Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Price Target of $32.43 According to Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned an average rating of “Hold” from the sixteen analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $32.43.

A number of equities research analysts recently weighed in on HIMS shares. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Morgan Stanley raised their price target on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Bank of America upped their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Hims & Hers Health Price Performance

Shares of HIMS opened at $28.96 on Friday. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $65.30. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The firm has a market cap of $6.76 billion, a price-to-earnings ratio of -45.97 and a beta of 2.44. The stock has a 50 day moving average of $29.28 and a 200-day moving average of $28.25.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue was up 38.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.17 earnings per share. As a group, analysts forecast that Hims & Hers Health will post -0.16 EPS for the current year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers and Hims Australia announced new management appointments, including chief medical officers for the UK and Australia. The moves could strengthen local clinical oversight and support the company’s international expansion strategy. Hims & Hers Names Chief Medical Officers in the UK and Australia
• Neutral Sentiment: Two insiders sold a combined 5,461 shares for approximately $160,357. Soleil Boughton sold 3,461 shares at an average of $29.17, while CFO Oluyemi Okupe sold 2,000 shares at $29.70. Both transactions were executed under pre-arranged Rule 10b5-1 plans, and each insider retained substantial holdings, reducing the significance of the sales as a standalone signal. SEC insider filing
• Negative Sentiment: Several law firms publicized a securities-fraud class action against Hims & Hers and certain executives. The lawsuit follows the FTC’s federal complaint, which allegedly concerns deceptive business practices and privacy-related misstatements or omissions. Investors who purchased shares between August 4, 2025, and July 29, 2026, have until November 2, 2026, to seek lead-plaintiff status. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around potential financial liability. Hagens Berman class-action announcement

Insider Activity

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total transaction of $398,226.53. Following the completion of the transaction, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at $12,964,577.40. The trade was a 2.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $29.70, for a total transaction of $59,400.00. Following the completion of the transaction, the chief financial officer owned 234,527 shares of the company’s stock, valued at approximately $6,965,451.90. This trade represents a 0.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 134,145 shares of company stock valued at $3,892,227. 11.76% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the business. QRG Capital Management Inc. acquired a new position in Hims & Hers Health during the 2nd quarter worth $248,000. Envestnet Portfolio Solutions Inc. increased its holdings in shares of Hims & Hers Health by 46.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company’s stock valued at $1,126,000 after purchasing an additional 10,366 shares during the period. Bienville Capital Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter valued at about $27,242,000. Engineers Gate Manager LP bought a new stake in shares of Hims & Hers Health during the second quarter valued at about $232,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Hims & Hers Health in the second quarter worth about $147,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.

Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.

The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.